<DOC>
	<DOC>NCT00868907</DOC>
	<brief_summary>Randomized, open-label, single dose, 3-treatment, 3-period crossover study, with a 14- to 17-day washout period between doses. The study will consist of a screening visit, study center admission (preceding Treatment Periods 1, 2 and 3), 3 treatment periods (4 days each), 1 washout period (14 to 17 days separating periods 1, 2 and 3), and exit procedures.</brief_summary>
	<brief_title>Study Assessing Dosing Time and Calcium and Vitamin D on the Relative BA of 35 mg DR Risedronate Dosed With Food</brief_title>
	<detailed_description />
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>female, 40 to 70 years of age nonlactating and either surgically sterile or postmenopausal body mass index less than or equal to 32 kg/m2 at screening no use of a bisphosphonate within 1 month no history of GI disease no use of any medications within 714 days prior to scheduled dosing day</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>